Modeling the use of triple combination therapy in five countries: Nevirapine, Zidovudine, and Didanosine

Value in Health

Volumn 3, Issue 3, 2000, Pages 186-201

  Biddle, Andrea K ^a,c   Simpson, Kit N ^b  

^a IL   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Acquired Immunodeficiency Syndrome; Anti HIV agents; Combination; Cost analysis; Cost benefit analysis; Costs; Drug therapy; HIV; Nevirapine

Indexed keywords

DIDANOSINE; NEVIRAPINE; ZIDOVUDINE;

ARTICLE; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; DRUG COST; DRUG RESEARCH; FRANCE; GERMANY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; PRIORITY JOURNAL; SPAIN; UNITED STATES;

EID: 0033869442     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.2000.33006.x     Document Type: Article

References (49)

1. Ioaniddis JPH, Sacks HS, Cappelleri JC, et al. Clinical efficacy of antiretroviral therapies in treatment-experienced HIV-infected patients: a meta-analysis. Online J Curr Clin Trials (serial online), 15 May 1997, Document #204.
2. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 1995;267:483-9.
3. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than predicted from fidelity of purified reverse transcriptase. J Virol 1995;69:5987-94.
4. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998. Updated recommendations of the International AIDS Society - USA Panel. JAMA 1998;280:78-86.
5. Gazzard B, Moyle G, on behalf of the BHIVA Guidelines Writing Committee. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998;352:314-6.
6. D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;124: 1019-30.
7. Montaner J, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. JAMA 1998;279:930-7.
8. Montaner J, Reiss P, Cooper D, et al. Long-term follow-up of patients treated with nevirapine (NVP) based combination therapy within the INCAS trial. Abstract 695. 5th Conference on Retroviruses and Opportunistic Infections; 1-5 February 1998; Chicago.
9. Simpson KN. Design and assessment of cost-effectiveness studies in AIDS populations. AIDS 1995;10(4 Suppl):S28-S32.
10. Mauskopf J, Simpson K. The costs and benefits of alternative drug treatment regimens for HIV patients. 3rd Conference on Retroviruses and Opportunistic Infections, Infectious Disease Society of America; 30 January 1996; Washington, DC.
11. Kempel A, Pleil AM, Willke RJ. Modelling costs and effectiveness of antiviral therapy under uncertainty of long-term efficacy. 6th European Conference on Clinical Aspects and Treatment of HIV Infection; 11-15 October 1997; Hamburg, Germany.
12. Simpson KN, LaVallee RL. Combination therapy in eight developed countries: events and costs of therapy with saquinavir, zalcitabine, and zidovudine therapy in Australia, Canada, Germany, Italy, Spain, Switzerland, UK, and USA. 3rd International Congress on Drug Therapy in HIV Infections; 5 November 1996; Birmingham, UK.
13. Schulman KA, Lynn LA, Glick HA, et al. Cost-effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann Intern Med 1991;114:798-802.
14. Moore RD, Bartlett JG. Combination antiretroviral therapy in HIV infection. PharmacoEconomics 1996;10:109-13.
15. 3 in five European countries. PharmacoEconomics 1994; 6:553-62.
16. Chancellor JV, Hill AM, Sabin CA, et al. Modelling the cost effectiveness of lamivudine/zidovudine combination therapy for HIV infection. PharmacoEconomics 1997;12:1-13.
17. Anis AH, Hogg RS, Wang X-H, et al. Modelling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy. PharmacoEconomics 1998;13:697-705.
18. Oddone E, Cowper P, Hamiton J, et al. Cost-effectiveness analysis of early zidovudine treatment of HIV infection patients. Br Med J 1993;307:1322-5.
19. Selvin S. Statistical Analysis of Epidemiological Data. New York: Oxford University Press, 1996:33.
20. 3. Multicenter AIDS Cohort Study. J Infect Dis 1994; 170:1280-7.
21. Colford JM Jr, Ngo L, Tager I. Factors associated with survival in human immunodeficiency virus-infected patients with very low CD4 counts. Am J Epidemiol 1995;141:788-9.
22. Kempel A, Barzaghi M, Bathie E, et al. Use and cost of health care resources for treating opportunistic infections in patients with HIV/AIDS. 3rd International Congress on Drug Therapy in HIV Infections; 5 November 1996; Birmingham, UK.
23. Brown R, Simpson KN, Nabulsi A. Cost and consequences of adding ritonavir to current antiviral therapy for advanced HIV patients in the United Kingdom and in the USA. XI International Conference on AIDS; 7-12 July 1996; Vancouver, Canada.
24. Staszewski S, Hill AM, Bartlett J, et al. Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials. AIDS 1997;11:477-83.
25. Cameron DW, Japour A, Mellors JW, et al. Antiretroviral safety & durability of ritonavir (RIT) - saquinavir (SAQ) in protease inhibitor-naive patients in year two followup. Abstract 388. 5th Conference on Retroviruses and Opportunistic Infections; 1-5 February 1998; Chicago.
26. Gulick RM, Mellors JW, Halvir D, et al. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection. JAMA 1998;280:35-41.
27. 3. Abstract 383. 5th Conference on Retroviruses and Opportunistic Infections; 1-5 February 1998; Chicago.
28. Markowitz M, Cao Y, Hurley A, et al. Virologic and immunologic response to triple therapy with nelfinavir in combination with AZT/3TC in 12 antiretroviral naïve HIV infected subjects at 10 months. Abstract 371. 5th Conference on Retroviruses and Opportunistic Infections; 1-5 February 1998; Chicago.
29. Cassano P, Hermans P, Sommereijns B, et al. Combined quadruple therapy with ritonavir-saquinavir (RTV-SQV) + nucleosides in patients who failed in triple therapy with RTV, SQV or indinavir (IDV). Abstract 423. 5th Conference on Retroviruses and Opportunistic Infections; 1-5 February 1998; Chicago.
30. Gallant JE, Hall C, Barnett S, et al. Ritonavir/ saquinavir (RTV/SQV) as salvage therapy after failure of initial protease inhibitor (PI) regimen. Abstract 427. 5th Conference on Retroviruses and Opportunistic Infections; 1-5 February 1998; Chicago.
31. Lawrence J, Schapiro J, Winters M, et al. Salvage therapy with indinavir plus nevirapine in patients previously treated with two other protease inhibitors and multiple reverse transcriptase inhibitors. Abstract 422. 5th Conference on Retroviruses and Opportunistic Infections; 1-5 February 1998; Chicago.
32. Mayers DL, Neaton JD, Perez G, et al. Prior saquinavir therapy leads to a models decrease in subsequent responses to drug regimens containing indinavir or ritonavir. Abstract 400. 5th Conference on Retroviruses and Opportunistic Infections; 1-5 February 1998; Chicago.
33. Tebas P, Kane E, Klebert M, et al. Virologic responses to ritonavir/saquinavir containing regimen in patients who have previously failed nelfinavir. Abstract 510. 5th Conference on Retroviruses and Opportunistic Infections; 1-5 February 1998; Chicago.
34. Laurence J. HAART regimens: do the effects last? A report from Toronto. AIDS Reader, Medscape. Available from http://www.medscape.com
35. Condra JH, Schlief WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-71.
36. Decks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997;277:145-53.
37. Drug Topics Red Book. Montvale, NJ: Medical Economics Co., 1997.
38. Nelfinavir: fourth protease inhibitor approved. Crit Path AIDS Proj 1997(Summer);32:31-2.
39. Organization for Economic Cooperation and Development (OECD). Main Economic Indicators. Paris: OECD Publications, October 1997.
40. United States Bureau of Labor Statistics. Consumer Price Index. Available from http://www.bls. gov/surveymost
41. Manning WG, Fryback DG, Weinstein MC. Reflecting uncertainty in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, et al., (eds.), Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
42. Johannesson M. On the discounting of gained life-years in cost-effectiveness analysis. Int J Technol Assess Health Care 1992;8(2):359-64.
43. Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold MR, Siegel JE, Russell LB, et al., (eds.), Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
44. United States Federal Reserve Board. International statistics. 3.28 Foreign exchange rates. Fed Reserve Bull 1998;84(4):A62.
45. Freedberg KA, Scharfstein JA, Seage GR III, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA 1998;279(2): 130-6.
46. Cook J, Dasbach E, Coplan P, et al. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: applications to a clinical trial. AIDS Res Hum Retroviruses 1999;15(6):499-508.
47. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992;146:473-81.
48. Kaspar R, Werntz G, DuBois DB. Early results of combined stavudine, lamivudine, and nevirapine: a twice daily, well tolerated protease inhibitor-sparing regimen for the treatment of HIV-1 infection. Abstract 669. 5th Conference on Retroviruses and Opportunistic Infections; 1-5 February 1998; Chicago.
49. Rieger A, Hein U, Schon H, et al. Nevirapine+ ddI+3TC - first experience with a once-daily dosing combination regimen. Abstract 697. 5th Conference on Retroviruses and Opportunistic Infections; 1-5 February 1998; Chicago.